drugset / Trial / NCT04755387

Ticagrelor De-escalation Strategy in AMI Patients

NCT04755387 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

DAPT de-escalation strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. The EASTYLE trial will evaluate a hybrid DAPT de-escalation strategy (reduced-dose ticagrelor, followed by aspirin early discontinuation) in AMI patients, compared with a conventional DAPT strategy.

Timeline

Start
2023-03-27
Primary completion
2027-01-15
Completion
2028-01-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 100 mg —
Subject Ticagrelor Small molecule 60 mg —
Subject Ticagrelor Small molecule 90 mg —